Estrogen action in human ovarian cancer

Critical Reviews in Oncology/Hematology

Volumn 25, Issue 1, 1997, Pages 1-9

  Clinton, Gail M ^a   Hua, Wenhui ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CATHEPSIN D; ESTROGEN; FIBULIN; FULVESTRANT; GENE PRODUCT; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PROGESTERONE RECEPTOR; TAMOXIFEN;

CARCINOMA CELL; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; OVARY CARCINOMA; REVIEW; RISK ASSESSMENT;

ANIMALS; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; MICE; OVARIAN NEOPLASMS;

EID: 0030889668     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(96)00216-8     Document Type: Review

References (96)

1. [1] Wingo PA, Tong T, Boldon S. Cancer statistics, 1995. CA Cancer J Clin 45:8-30, 1995.
2. [2] Dietl J, Marzusch K. Ovarian surface epithelium and human ovarian cancer. Gynecol Obstet Invest 35:129-135, 1993.
3. [3] van der Burg MEL, van Lent M, Buyse M. et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332:629-634, 1995.
4. [4] Pettersson F. Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 36:(Suppl)1-315, 1991.
5. [5] Rao BR, Slotman, BJ. Endocrine factors in common epithelial ovarian cancer. Endocrin Rev 12:14-26, 1991.
6. [6] Rosenberg L, Shapiro S, Stone D et al. Epithelial ovarian cancer and combination oral contraceptives. JAMA 247:3210-3212, 1982.
7. [7] Tavani A, Negri E, Franceschi S et al. Risk factors for epithelial ovarian cancer in women under age 45. Eur J Cancer 29A:1297-1301, 1993.
8. [8] Herbst AL, Besek JS. Impact of contraception on gynecologic cancers. Am J Obstet Gynecol 168:1980-1985, 1993.
9. [9] Whitmore AS, Harris E, Itnyre J, and the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. Am J Epidemiol 136:1184-1203, 1992.
10. [10] Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 331:771-776, 1994.
11. [11] Rodriguez C, Calle EE, Coates RJ, Miracle-McMahill HL, Thun MJ, Heath CW, Jr. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 141:828-835, 1995.
12. [12] Weiss NS, Lyon JL, Krishnamurthy S et al. Noncontraceptive estrogen use and the occurrence of ovarian cancer. JNCI 68:95-96, 1982.
13. [13] Cramer DW, Hutchinson OB, Welch WR et al. Determinants of ovarian cancer risk. I Reproductive experiences and family history. JNCI 71:711-716, 1983.
14. [14] Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case control study. Br J Cancer 60:592-598, 1989.
15. [15] Kaufman DW, Kelly JP, Welch WR et al. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 130:1142-1151, 1989.
16. [16] Hartge P, Hoover R, McGowan L, LeSher L, Norris HJ. Menopause and ovarian cancer. Am J Epidemiol 127:990-998, 1988.
17. [17] Falhalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet 2:163, 1971.
18. [18] Emons G, Pahwa GS, Ortmann O, Knuppen R, Oberheuser F, Schulz K-D. LHRH-receptors and LHRH-agonist treatment in ovarian cancer: an overview. J Steroid Biochem Mol Biol 37:1003-1006, 1990.
19. [19] Cramer DW, Welch WR. Determinants of ovarian cancer risk. II Inferences regarding pathogenesis. J Natl Cancer Inst 71:717-721, 1983.
20. [20] Orth K, Hung J, Gazdar A, Bowcock A, Mathis JM, Sambrook J. Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci USA 91:9495-9499, 1994.
21. [21] Russell SEH, Hickey GI, Lowry WS, White P, Atkinson RJ. Allele loss from chromosome 17 in ovarian cancer. Oncogene 5:1581 1583, 1990.
22. [22] Nash, JD, Ozols RF, Smyth JF, Hamilton TC. Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstet Gynecol 6:1009-1016, 1989.
23. [23] Geisinger KM, Berens ME, Duckett Y, Morgan TM, Kute TE, Welander CE. The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro. Cancer 65:1055-1061, 1990.
24. [24] Langdon SP, Hawkes MM, Lawrie SS, et al. Oestrogen receptor expression and the effects of estrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br J Cancer 62:213-216, 1990.
25. [25] Sawada M, Terada N, Wada A, et al. Estrogen and androgen-responsive growth of human ovarian adenocarcinoma hetero-transplanted into nude mice. Int J Cancer 45:359-363, 1990.
26. [26] Pavlik EJ, Nelson K, Nagell JV, et al. The growth response of BG-1 ovarian carcinoma cells to estradiol, 4OH-tamoxifen, and tamoxifen: evidence for intrinsic antiestrogen activation. Gynecol Oncol 42:245-249, 1991.
27. [27] Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H. Estradiol stimulates cell growth and secretion of procathepsin D and a 120-Kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 75:1497-1502, 1992.
28. [28] Wimalasena J, Meehan D, Dostal R, Foster JS, Cameron M, Smith Mc. Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors. Oncology Res 5:325-337, 1993.
29. [29] Langdon SP, Crew AJ, Ritchie AA, et al. Growth inhibition of estrogen receptor-positive human ovarian carcinoma by anti-estrogens in vitro and in a xenograft model. Eur J Cancer 30A:682-686, 1994.
30. [30] Langdon SP, Hirst GL, Miller EP, et al. The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. J Steroid Biochem Mol Biol 50:131-135, 1994.
31. [31] Maass H, Jonat W, Stolzenbach G, Trams G. The problem of nonresponding estrogen-receptor positive patients with advanced breast cancer. Cancer (Phila) 6:2835-2837, 1980.
32. [32] Glauber, JG, Kiang, DT. The changing role of hormonal therapy in advanced breast cancer. Sem Oncol 19:308-316, 1992.
33. [33] Kommoss F, Pfisterer J, Thome M, Geyer H, Sauerbrei W, Pfleiderer A. Estrogen and progesterone receptors in ovarian neoplasms: discrepant results of immunohistochemical and biochemical results. Int J Gynecol Cancer 1:147-153, 1991.
34. [34] Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfleiderer A. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol 47:317-322, 1992.
35. [35] Chien C-H, Wang F-F, Hamilton TC. Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells. Mol Cell Endocrinol 99:11-19, 1994.
36. [36] Hua W, Christianson T, Rougeot C, Rochefort H, Clinton GM. SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth resistant to estrogen and antiestrogens. J Steroid Biochem Mol Biol 55:279-289, 1995.
37. [37] Slotman BJ, Rao BR, Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy, and endocrine therapy. Anticancer Res 8:417-434, 1988.
38. [38] Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. Cancer 68:269-271, 1991.
39. [39] Ahlgren JD, Ellison NM, Gottlieb RJ, et al. Hormone palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 11:1957-1968, 1993.
40. [40] Wimalasena J, Meehan D, Cavallo C. Human epithelial ovarian cancer cell steroid secretion and its control by gonadotropins. Gynecol Oncol 41:56-63, 1991.
41. [41] Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812-815, 1988.
42. [42] Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2818, 1990.
43. [43] Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endo 9:443-456, 1995.
44. [44] Wakeling AE. Therapeutic potential of pure antiestrogens in the treatment of breast cancer. J Steroid Biochem Mol Biol 37:771-775, 1990.
45. [45] Wakeling AE. Are breast tumors resistant to tamoxifen also resistant to pure antiestrogens? J Steroid Biochem Mol Biol 47:107-114, 1993.
46. [46] Wakeling AE. The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 25:1-9, 1993.
47. [47] Lippman Me, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long-term tissue culture. Cancer Res 36:4595-4601, 1976.
48. [48] Rochefort, H. Oestrogens, proteases and breast cancer. From cell lines to clinical applications. Eur J Cancer 30A:1583-1586, 1994.
49. [49] Geisinger KR, Kute TE, Pettenati MJ, et al. Characterization of an human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer 63:280-288, 1989.
50. [50] Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice, J Natl Cancer Inst 59:221-226, 1977.
51. [51] Hamilton TC, Young RC, McKoy WM, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43:5379-5389, 1983.
52. [52] Fogh J, Tempe G. New human tumor cell lines. In: Fogh J, ed. Human Tumor Cells in vitro. New York: Plenum Press, 1975; 115-159.
53. [53] Langdon SP, Lawrie SS, Hay FG, et al. Characterization and properties of 9 human ovarian adenocarcinoma cell lines. Cancer Res 48:6166-6172, 1988.
54. [54] Langdon SP, Ritchie A, Young K, et al. Contrasting effects of 17 β-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo. Int J Cancer 55:459-464, 1993.
55. [55] Dickson RB, Lippman ME. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocrin Rev 8:29-43, 1987.
56. [56] Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103:1742-1751, 1978.
57. [57] Hamilton TC, Behrens BC, Louie KG, Ozols RF. Induction of progesterone receptor in human ovarian cancer. J Clin Endocrinol Metab 59:561-563, 1984.
58. [58] Scambia G, Panici PB, Ferrandina G, Battaglia F, Baiocchi G, Mancuso S. Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for estrogen, progesterone and epidermal growth factor. Br J Cancer 64:182-184, 1991.
59. [59] Scambia G, Panici PB, Ferrandina G, et al. Clinical significance of cathepsin D in primary ovarian cancer. Eur J Cancer 30A:935-940, 1994.
60. [60] Watson PH, Pon RT, Shiu RP. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotides identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51:3996-4000, 1991.
61. [61] Schuchard M, Landers JP, Sandhuy NP, Spelsberg TC. Steroid hormone regulation of nuclear proto-oncogenes. Endocrin Rev 14:659-669, 1993.
62. [62] Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. c-myc amplification in ovarian cancer. Gynecol Oncol 38:340-342, 1990.
63. [63] Schreiber G, Dubeau L. c-myc proto-oncogene amplification detected by polymerase chain reaction in archival human ovarian carcinomas. Am J Pathol 137:653-658, 1990.
64. [64] Watson JV, Curling OM, Munn CF, Hudson CN. Oncogene expression in ovarian cancer: a pilot study of c-myc oncoprotein in serous papillary ovarian cancer. Gynecol Oncol 28:137-150, 1987.
65. [65] Polacarz SV, Hey NA, Stephenson TJ, Hill AS. c-myc oncogene product p62c-myc in ovarian mucinous neoplasms: immunohistochemical study correlated with malignancy. J Clin Pathol 42:148-152, 1989.
66. [66] Masiakowski P, Breathnach R, Bloch J, Cannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 10:7895, 1982.
67. [67] Nunez AM, Jakowlev S, Briand JP, et al. Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7. Endocrinology 121:1759, 1987.
68. [68] Foekens JA, Rio MC, Seguin P, et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50:3832, 1990.
69. [69] Wysocki SJ, Hahnel E, Masters A, Smith V, McCartney AJ, Hahnel R. Detection of pS2 messenger RNA in gynacelogical cancers. Cancer Res 50:1800-1805, 1990.
70. [70] Henry JA, Bennet MK, Piggott NH, Levett DL, May FEB, Westley BR. Expression of the sNR-2pS2 protein in diverse human epithelial tumors. Br J Cancer 64:677-682, 1991.
71. [71] Fokens JA, van Putten WLJ, Portengen H, et al. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-r), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J Steroid Biochem Mol Biol 37:815-821, 1990.
72. [72] Clinton, GM, Rougeot C, Derancourt J, et al. Estrogens increase the expression of fibulin-1, an extracellular matrix protein, secreted by human ovarian cancer cells. Proc Natl Acad Sci USA 93:316-320, 1996.
73. [73] Balbona K, Tran H, Godyna S, Ingham KC, Strickland DK, Argraves WS. Fibulin binds to itself and to the carboxyl-terminal heparin binding region of fibronectin. J Biol Chem 267:20120-20125, 1992.
74. [74] Pan T-C, Kluge RZ, Mayer U, Timpl R, Chu M-L. Sequence of extracellular mouse protein BM-90/fibulin and its calcium-dependent binding to other basement-membrane ligands. Eur J Biochem 215:733-740, 1993.
75. [75] Roark EF, Keene DS, Haudenschild CC, Godyna S, Little CD, Argraves WS. The association of human fibulin-1 with elastic fibers: an immunohistological, ultrastructural, and RNA study. J Histochem Cytochem 43:401-411, 1995.
76. [76] Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989.
77. [77] Zhang X, Silva E, Gershenson D, Hung M-C. Amplification and rearrangement of c-erbB proto-oncogenes in cancer of human female genital tract. Oncogene 4:985-989, 1989.
78. [78] Kury FD, Schneeberger C, Sliutz G. et al. Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation. Oncogene 5:1403-1408, 1990.
79. [79] Haldane JS, Hird V, Hughes CM, Gullick WJ. c-erb-B-2 oncogene expression in ovarian cancer. J Pathol 162:321-237, 1990.
80. [80] Mandai M, Konishi I, Koshiyama M, et al. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology. EGFR, c-erbB-2, and c-erB-3 genes, and sex steroid receptor expression. Cancer Res 54:1825-1830, 1994
81. [81] Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor-survival in advanced epithelial ovarian cancer. Cancer Res 50:4087-4091, 1990.
82. [82] Read LD, Keith DJ, Katzenellenbogen BS. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50:3947-3951, 1990.
83. [83] Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M. Inhibition of c-erbB2 oncogene expression by estrogens in human breast cancer cells. Oncogene 7:1001-1006, 1990.
84. [84] Russel KS, Hung M-C. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res 52:6624-6629, 1992.
85. [85] Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepare HM, Osborne CK. Estrogen-dependent, tamoxifen resistant tumorigenic growth of MCF-7 cells transfected with HER-2/neu. Br Cancer Res Treat 24:85-95, 1992.
86. [86] Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446, 1995.
87. [87] Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992.
88. [88] Miki Y, Swenson J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994.
89. [89] Merajiver SD, Pham TM, Caduff RF, et al. Somatic mutations in the Brcal gene in sporadic ovarian tumours. Nature Genet 9:439-443, 1995.
90. [90] Hosking L, Trowsdale J, Nicolai H, et al. A somatic Brcal mutation in an ovarian tumor. Nature Genet 9:343-344, 1995.
91. [91] Futreal PA, Liu Q, Shattuck-Eidens D, et al. Brcal mutations in primary breast and ovarian carcinomas. Science 266:120-122, 1994.
92. [92] Ford D, Easton DF, Bishop DT, et al. Risks of cancer in Brca 1-mutation carriers. Lancet 343:692-695, 1994.
93. [93] Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin G-Y, Abel KJ, Weber BL, Chodosh LA. The developmental pattern of Brcal expression implies a role in differentiation of the breast and other tissues. Nature Genet 11:17-26, 1995.
94. [94] Nawata H, Bronzest D, Lippman ME. Isolation and characterization of a tamoxifen resistant cell line derived from MCF-7 human breast cancer cells. J Biol Chem 256:5016-5021, 1981.
95. [95] Katzenellenbogen BS, Kendra KL, Normal JM, Berthois Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogen. Cancer Res 47:4355-4360, 1987.
96. [96] Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line MCF-7/TAMR-1. Cancer Res 54:1587-1595, 1994. Gail M. Clinton received her Ph.D. from the University of California at San Diego. She did a postdoctoral fellowship at Harvard Medical School and is currently an associate professor at Oregon Health Sciences University in Portland. Wenhui Hua received her Ph.D. from Oregon Health Sciences University and is currently a postdoctoral fellow at the University of Washington in Seattle.